PALO
ALTO, Calif., Nov. 11,
2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
a broad spectrum of retinal diseases, announced today that
management will present at the following upcoming investor
conferences. Members of the management team will also be available
for one-on-one meetings.
- Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM
GMT (1:00 AM PT), London, UK
- 7th Annual Evercore ISI HealthCONx Conference,
December 3, 2024, 2:35 PM ET (11:35 AM
PT), Coral Gables,
Florida
A live webcast of both presentations will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for a
limited time following the events.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company
committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABCD Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABCD Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases. Tarcocimab
is currently being studied in two Phase 3 clinical trials, GLOW2 in
patients with diabetic retinopathy and DAYBREAK in patients with
wet AMD. Both studies are actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting disease biology beyond VEGF for differentiated
efficacy. The Phase 3 DAYBREAK study of KSI-501 in wet AMD is
actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6,
VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the
treatment of retinal inflammatory diseases, as currently there are
no available intravitreal biologic therapies addressing the
spectrum of inflammatory conditions of the retina. The Phase
1b APEX study of KSI-101 is actively
enrolling patients, as a precursor to activating the Phase
2b/3 PEAK and PINNACLE studies in
patients with macular edema secondary to inflammation (MESI).
Kodiak is advancing its Antibody Biopolymer Conjugate Drug
(ABCD) Platform that embeds small molecules and other active
pharmaceutical ingredients ("APIs") into Kodiak's proprietary
biopolymer backbone to enable high drug-antibody-ratio ("DAR")
medicines. The diverse APIs are designed to be released over time
to achieve targeted, multi-specific and tailored modulation of
biological pathways. The unique combination of high DAR and
tailored therapeutic benefit offers potential for broad application
to multifactorial diseases and builds directly from our Antibody
Biopolymer Conjugate technology and its 15 years of design,
development and manufacturing experience.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-participate-in-upcoming-investor-conferences-302300603.html
SOURCE Kodiak Sciences Inc.